Pediatric Hodgkin Lymphoma: Predictive value of interim 18F-FDG PET/CT in therapy response assessment - Wikidata - awgldk - TriplyDB

Pediatric Hodgkin Lymphoma: Predictive value of interim 18F-FDG PET/CT in therapy response assessment

Pediatric Hodgkin Lymphoma: Predictive value of interim 18F-FDG PET/CT in therapy response assessment

http://www.wikidata.org/entity/Q30363610

about

Tyrosine-Kinase Inhibitors Therapies with Mainly Anti-Angiogenic Activity in Advanced Renal Cell Carcinoma: Value of PET/CT in Response Evaluation.

P2860

Q41660750-B1B4A6D2-4D87-4C56-8785-0745512BADF8

P2860

Pediatric Hodgkin Lymphoma: Predictive value of interim 18F-FDG PET/CT in therapy response assessment

http://www.wikidata.org/entity/Q30363610

description

2017 nî lūn-bûn

@nan

2017 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2017 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

name

Pediatric Hodgkin Lymphoma: Pr ...... in therapy response assessment

@ast

Pediatric Hodgkin Lymphoma: Pr ...... in therapy response assessment

@en

type

label

Pediatric Hodgkin Lymphoma: Pr ...... in therapy response assessment

@ast

Pediatric Hodgkin Lymphoma: Pr ...... in therapy response assessment

@en

prefLabel

Pediatric Hodgkin Lymphoma: Pr ...... in therapy response assessment

@ast

Pediatric Hodgkin Lymphoma: Pr ...... in therapy response assessment

@en

P1433

Q30363610-D88E2A3D-7766-4D7B-B4C4-86E9C3419284

P1476

Q30363610-A64D6A19-8F6C-4053-B5AA-1F78AC4ACA19

P2093

Q30363610-1A786666-BE4C-438E-97E5-5F82BCB724FD

Q30363610-1DF48313-D33B-46BE-B67D-AEA30B570AA4

Q30363610-1E3CBA0C-449E-4613-862D-723FC42F979A

Q30363610-4D0FEB05-8100-4D68-AA80-632857B43B4F

Q30363610-5464C88C-0DA5-4125-84AE-B2527739310D

Q30363610-7685E8DD-1E91-46F6-94FA-B1699A1BEAD3

Q30363610-C21848DA-E4A3-42A4-8758-9B1322F9629B

Q30363610-C76BAADB-F562-4AE6-AF05-2A2460BD4A5D

P2860

Q30363610-00C2758E-4975-4B96-87E5-7756E7E80BAC

Q30363610-0DE33607-EDEF-4AF1-9FBC-FE7440577394

Q30363610-1401344B-E5C2-4FBA-B22A-604D020F7235

Q30363610-205755DB-E0E5-40A9-B137-0CED5A4E886E

Q30363610-367CE282-D2AC-4B93-A3BC-111950F8B73D

Q30363610-3A8691CF-EF29-4022-B029-269DDEC40A7E

Q30363610-3D031474-DFC7-4CCC-9868-4DACFB002EF1

Q30363610-636D4D25-D490-4117-BB25-9AD5C5208786

Q30363610-6C73DC7B-A105-4385-B367-B68677CEDF23

Q30363610-6E337CB6-58F9-49E2-B17C-39F9D1AE86E2

P304

Q30363610-FB75C9AC-482B-488A-9280-CDBBF2896C62

P31

Q30363610-A55384C3-1F95-4355-AFA1-F3E9C3836B2A

P356

Q30363610-655F94D5-947B-4600-B881-627019CC1696

P407

Q30363610-4803AD18-1C4F-4D93-A23A-12C830DC2BC4

P433

Q30363610-D8F566A2-68AF-4EEC-A6FC-FDAFACD2EA68

P478

Q30363610-78F730D9-51F3-447F-933D-65626604CB03

P50

Q30363610-24A958D9-5FA0-460A-882D-7D660EA1A79C

Q30363610-5FC9D783-0993-49B8-9E2A-72ACA921BAF9

P577

Q30363610-E076E538-1358-450B-8395-1DFD675CB371

P698

Q30363610-A80480E9-8D4F-4B63-B6A7-114993E763E1

P932

Q30363610-8BF7ED44-FB8F-4049-A9EB-F6DD5DF063E1

P356

MD.0000000000005973

P1433

P1476

Pediatric Hodgkin Lymphoma: Pr ...... in therapy response assessment

@en

P2093

Corinna Altini

http://www.w3.org/2001/XMLSchema#string

Cristina Ferrari

http://www.w3.org/2001/XMLSchema#string

Francesco De Leonardis

http://www.w3.org/2001/XMLSchema#string

Giuseppe Rubini

http://www.w3.org/2001/XMLSchema#string

Nicola Santoro

http://www.w3.org/2001/XMLSchema#string

Nunzio Merenda

http://www.w3.org/2001/XMLSchema#string

Paola Muggeo

http://www.w3.org/2001/XMLSchema#string

Teresa Perillo

http://www.w3.org/2001/XMLSchema#string

P2860

International validation study for interim PET in ABVD-treated, advanced-stage hodgkin lymphoma: interpretation criteria and concordance rate among reviewers.

Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting.

The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications

FDG-PET Response Prediction in Pediatric Hodgkin's Lymphoma: Impact of Metabolically Defined Tumor Volumes and Individualized SUV Measurements on the Positive Predictive Value.

Inter-Reader Reliability of Early FDG-PET/CT Response Assessment Using the Deauville Scale after 2 Cycles of Intensive Chemotherapy (OEPA) in Hodgkin's Lymphoma

Role of imaging in the staging and response assessment of lymphoma: consensus of the International Conference on Malignant Lymphomas Imaging Working Group.

The role of 18F-FDG PET and 18F-FDG PET/CT in the evaluation of pediatric Hodgkin's lymphoma and non-Hodgkin's lymphoma.

18F-FDG PET after 2 cycles of ABVD predicts event-free survival in early and advanced Hodgkin lymphoma.

Early and late therapy response assessment with [18F]fluorodeoxyglucose positron emission tomography in pediatric Hodgkin's lymphoma: analysis of a prospective multicenter trial.

Long-term survival and competing causes of death in patients with early-stage Hodgkin's disease treated at age 50 or younger.

P304

e5973

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1097/MD.0000000000005973

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

96

http://www.w3.org/2001/XMLSchema#string

P50

Margherita Fanelli

Artor Niccoli Asabella

P577

2017-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28151888

http://www.w3.org/2001/XMLSchema#string

P932

5293451

http://www.w3.org/2001/XMLSchema#string